Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity.
about
Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitorsTargeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer TreatmentThe relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivoNimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II studyCancer targeted therapeutics: From molecules to drug delivery vehicles.The emerging role of nimotuzumab in the treatment of non-small cell lung cancer.Development of an ErbB-overexpressing A-431 optical reporting tumor xenograft model to assess targeted photodynamic therapy regimens.Rash rates with egfr inhibitors: meta-analysis.Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.Control of advanced cancer: the road to chronicity.Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair.The challenges and the promise of molecular targeted therapy in malignant gliomas.Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for ImmunotherapyA pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical EffectsTherapeutic approaches to target cancer stem cells.Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experienceA randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.Nimotuzumab for pediatric diffuse intrinsic pontine gliomas.Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody.Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancerEGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors.Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer.Going native: Direct high throughput screening of secreted full-length IgG antibodies against cell membrane proteins.
P2860
Q26750719-F0D4C632-BB5F-43E1-BA4F-3D320C51F4E3Q26769963-910C8B05-02AF-4B28-B07B-C3232C2E74D7Q27853223-6D9E1D1B-18D5-4837-B87A-D1B89700BB26Q27853322-5B84928D-99C5-47EB-BF55-8938F9E7F0E4Q33779303-53896010-3882-4209-BC1B-6C012EA99B19Q33887986-0DE73C66-B39F-4694-B12C-6E854E64A5A0Q34343043-017FDE49-B5B8-4EA7-8273-D5A7D606BD04Q34349345-6531293B-8A84-4FE8-9398-4BBD0D9E18D4Q34761646-DAD0E4CD-2699-4ADC-9483-79E8E0220E8AQ34778047-B9FFD95A-BFD5-40F4-9CFC-CF1AA3950CAEQ34874471-5043E6F5-006D-4FFC-9B4A-A37708D328D4Q35142705-8414E4D3-E12C-41A9-8091-90E322003CB0Q35214534-7F7DF74A-552D-4514-93AE-F8A492ED5239Q35534349-85ACF4FC-3A44-43EC-8C02-B082BF8D9212Q35623476-4CD175C3-7CBD-4D1E-BEE3-56B6060EB9C1Q36214463-E43AEF54-700D-49FA-B21E-7E8F1136B188Q37132708-D0D7419C-1A63-465A-8D19-1FEA2EF5CA36Q37137412-D4A16A94-C547-4C93-9A3F-4FFC66CA0492Q37362948-58E9376D-12A6-4673-96AD-77888915FCA1Q37716649-874B7DEF-5913-4D98-9CBF-D3BBA6783BD4Q37719187-8246E862-6D7C-414D-9550-0BB0A1F76D61Q37822466-D05BA810-8D16-420B-BF4B-CD78E947C46BQ38021521-F78770C4-D75C-4D4E-BB17-76FBA6A01E01Q38214511-B9905A1C-FE2B-4E5C-A6FC-D28D4586B0D4Q39093873-117AC6E2-B307-4F52-B68D-4602598DFB17Q39139857-ABD297A6-DF40-4304-A5ED-7B7E30614C18Q41855293-C74C63EF-F1C5-4533-9BFC-6AAAB56DF979Q43439165-B539A673-BF42-49CE-BD54-F0911B586C09Q44656784-625F956F-8B1A-4B8D-891F-8121CB509A2BQ46426888-C4C09443-AB1F-4809-84F1-20B7911E28A5Q49965756-D9190BD5-A639-43AF-9B25-5B5B10F6CF04
P2860
Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nimotuzumab: a novel anti-EGFR ...... hile minimizing skin toxicity.
@en
Nimotuzumab: a novel anti-EGFR ...... hile minimizing skin toxicity.
@nl
type
label
Nimotuzumab: a novel anti-EGFR ...... hile minimizing skin toxicity.
@en
Nimotuzumab: a novel anti-EGFR ...... hile minimizing skin toxicity.
@nl
prefLabel
Nimotuzumab: a novel anti-EGFR ...... hile minimizing skin toxicity.
@en
Nimotuzumab: a novel anti-EGFR ...... hile minimizing skin toxicity.
@nl
P2860
P1476
Nimotuzumab: a novel anti-EGFR ...... hile minimizing skin toxicity.
@en
P2093
William Kells Boland
P2860
P304
P356
10.1517/14712590903110709
P407
P577
2009-09-01T00:00:00Z